Nufactor® Receives U
Nufactor® Receives URAC’s Full Certification as a Rare Disease Pharmacy Center of Excellence
17 sept. 2024 13h34 HE | FFF Enterprises.com
TEMECULA, Calif., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nufactor, Inc., a specialty infusion company and subsidiary of FFF Enterprises, Inc., is delighted to announce that it has received full...
NOVARTIS logo.jpg
Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN)
07 août 2024 19h30 HE | Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Fabhalta achieved a 44% proteinuria reduction from baseline in Phase III APPLAUSE-IgAN interim analysis, compared with 9% in placebo arm, demonstrating a...
Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone
01 août 2024 09h00 HE | PRISM Mediawire
Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone
Jeanne Schow, Senior Vice President, Business Development
Avance Clinical Announces Senior Appointment to North American Operations
31 juil. 2024 02h45 HE | Avance Clinical
ADELAIDE, Australia and WAKE FOREST, N.C., July 31, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, an award-winning, mid-sized full-service global Contract Research Organization (CRO) for biotech...
PMV main logo.png
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
15 juil. 2024 10h16 HE | PRISM MarketView
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
About Jura Health
Jura Health Welcomed by Colorado Medicaid as an Approved Provider for Testing for Suspected Rare Diseases
20 juin 2024 11h55 HE | Innosphere Ventures
Denver, Colorado, June 20, 2024 (GLOBE NEWSWIRE) -- Jura Health, an Innosphere Ventures client company, committed to health equity for rare disease patients and their families, is pleased to...
Soligenix
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
05 juin 2024 08h00 HE | PRISM MarketView
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
New 2024 TrialWire Logo (600 x 500 px) (400 x 100 px) (600 x 200 px) (3).png
TrialWire Patient Recruitment Platform that Reboots Stalled Clinical Trials announced as Multi-Award Finalist in the 2024 Citeline Awards
12 mai 2024 16h29 HE | TrialWire
The TrialWire™ Rapid Patient Recruitment Platform, the only pay-per-enrolled fixed-fee solution powered by AI and algorithms, has been select for 3 awards
baylor-logo-wire-1200x628.jpg
Using AI to Improve Diagnosis of Rare Genetic Disorders
25 avr. 2024 09h19 HE | Baylor Genetics
Diagnosing rare Mendelian disorders is a labor-intensive task, even for experienced geneticists. Investigators at Baylor College of Medicine are trying to
SMDG color logo with name rgb1.jpg
SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors
14 mars 2024 05h00 HE | S. M. Discovery Group (SMDG)
SMDG Announces Appointment of Industry Leader Dr. Zsuzsanna Devecseri to the Board of Directors